@article{Hosseini Mehr_Dzekunova_Smorzhevskyi_2022, title={Criteria for choosing anticoagulant therapy in COVID19 patients}, volume={9}, url={https://medscidiscovery.com/index.php/msd/article/view/818}, DOI={10.36472/msd.v9i10.818}, abstractNote={<p><strong>Objective: </strong>While COVID-19 continues to circulate around the world, there are still many uncertainties on how to treat patients infected with the potentially deadly virus and, more importantly, for how long!</p> <p>COVID-19 causes many different symptoms, among which coagulopathy seems to play an essential role in the survival prognosis of patients. While WHO recommends thromboprophylaxis in all admitted covid patients, it is still not routinely used in many medical centers worldwide. It is also worth mentioning that there is no animosity on the anticoagulant agents’ choice or the duration they should be prescribed. Recent data suggest that it is wise to prescribe a prophylactic dose of anticoagulant for a minimum of 3 months post-discharge to minimize the risk of thrombosis in COVID-19 patients.</p>}, number={10}, journal={Medical Science and Discovery}, author={Hosseini Mehr, Seyed Pouriya and Dzekunova, Yuliia and Smorzhevskyi, Valentyn}, year={2022}, month={Oct.}, pages={555–557} }